Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Dasatinib-blinatumomab for ALL

Robin Foà • 14 Jun 2019
EHA 2019
Acute Lymphoblastic Leukemia Blinatumomab
GIMEMA LAL2116

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses a dasatinib-blinatumomab combination for the frontline treatment of adult Philadelphia positive acute lymphoblastic leukemia (ALL). Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Foà discusses preliminary results of the GIMEMA LAL2116 trial (NCT02744768).

More from Robin Foà

5:14
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals